Editas Medicine (EDIT) – Hot FDA News
-
Editas Medicine (EDIT) Declines 18% Following Proof of Concept of EDIT-101 from Phase 1/2 BRILLIANCE Trial
-
Editas Medicine (EDIT) Declines 12.5% Following Clinical Data from Ongoing Phase 1/2 BRILLIANCE Clinical Trial of EDIT-101 for LCA10
-
-
-
-
Back to EDIT Stock Lookup